A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
United States: Food and Drug Administration
AVF2938g
NCT00081614
March 2004
July 2005
Name | Location |
---|---|
UCLA School of Medicine | Los Angeles, California 900121973 |
Stanford University Medical Center | Stanford, California 94305-5408 |
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Beth Israel Deaconess Medical Center | Boston, Massachusetts 02215 |
Bennett Cancer Center | Stamford, Connecticut 06902 |
North Shore University Hospital | Manhasset, New York 11030 |
Our Lady of Mercy Medical Center | Bronx, New York 10466 |
Kaiser Permanente Medical Group | Los Angeles, California 90027 |
Ochsner Cancer Institute | New Orleans, Louisiana 70121 |
University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
St. Joseph Oncology | St. Joseph, Missouri 64507 |
Bay Area Cancer Research Group | Concord, California 94520 |
NYU School of Medicine | New York, New York 10016 |
Raleigh Hematology Oncology | Cary, North Carolina |
The Cleveland Clinic | Cleveland, Ohio 44195 |
UCHSC - Urologic Oncology | Aurora, Colorado 80010 |
Lynn Regional Cancer Center - West | Boca Raton, Florida 33428 |
Wayne State University / Harper University Hospital | Detroit, Michigan 48201 |
The Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey 07601 |
Northwestern Carolina Oncology & Hematology | Hickory, North Carolina 28601 |